REDWOOD CITY, Calif., April 14, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced three presentations regarding its hypoxia-activated prodrug (HAP) platform, which includes the lead HAP candidate, TH-302. The presentations took place on Sunday, April 13 at the 2008 American Association for Cancer Research (AACR) annual meeting in San Diego, CA.
